Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib

N. Prokoph, JD. Matthews, RM. Trigg, IA. Montes-Mojarro, GAA. Burke, F. Fend, O. Merkel, L. Kenner, B. Geoerger, R. Johnston, MJ. Murray, C. Riguad, L. Brugières, SD. Turner

. 2023 ; 202 (5) : 985-994. [pub] 20230625

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23016389

Anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by the oncogenic anaplastic lymphoma kinase (ALK), accounting for approximately 15% of all paediatric non-Hodgkin lymphoma. Patients with central nervous system (CNS) relapse are particularly difficult to treat with a 3-year overall survival of 49% and a median survival of 23.5 months. The second-generation ALK inhibitor brigatinib shows superior penetration of the blood-brain barrier unlike the first-generation drug crizotinib and has shown promising results in ALK+ non-small-cell lung cancer. However, the benefits of brigatinib in treating aggressive paediatric ALK+ ALCL are largely unknown. We established a patient-derived xenograft (PDX) resource from ALK+ ALCL patients at or before CNS relapse serving as models to facilitate the development of future therapies. We show in vivo that brigatinib is effective in inducing the remission of PDX models of crizotinib-resistant (ALK C1156Y, TP53 loss) ALCL and furthermore that it is superior to crizotinib as a second-line approach to the treatment of a standard chemotherapy relapsed/refractory ALCL PDX pointing to brigatinib as a future therapeutic option.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016389
003      
CZ-PrNML
005      
20231026105933.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.18953 $2 doi
035    __
$a (PubMed)37357529
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Prokoph, Nina $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
245    10
$a Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib / $c N. Prokoph, JD. Matthews, RM. Trigg, IA. Montes-Mojarro, GAA. Burke, F. Fend, O. Merkel, L. Kenner, B. Geoerger, R. Johnston, MJ. Murray, C. Riguad, L. Brugières, SD. Turner
520    9_
$a Anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by the oncogenic anaplastic lymphoma kinase (ALK), accounting for approximately 15% of all paediatric non-Hodgkin lymphoma. Patients with central nervous system (CNS) relapse are particularly difficult to treat with a 3-year overall survival of 49% and a median survival of 23.5 months. The second-generation ALK inhibitor brigatinib shows superior penetration of the blood-brain barrier unlike the first-generation drug crizotinib and has shown promising results in ALK+ non-small-cell lung cancer. However, the benefits of brigatinib in treating aggressive paediatric ALK+ ALCL are largely unknown. We established a patient-derived xenograft (PDX) resource from ALK+ ALCL patients at or before CNS relapse serving as models to facilitate the development of future therapies. We show in vivo that brigatinib is effective in inducing the remission of PDX models of crizotinib-resistant (ALK C1156Y, TP53 loss) ALCL and furthermore that it is superior to crizotinib as a second-line approach to the treatment of a standard chemotherapy relapsed/refractory ALCL PDX pointing to brigatinib as a future therapeutic option.
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a anaplastická lymfomová kináza $7 D000077548
650    _2
$a krizotinib $x farmakologie $x terapeutické užití $7 D000077547
650    12
$a nemalobuněčný karcinom plic $7 D002289
650    _2
$a tyrosinkinasové receptory $x terapeutické užití $7 D020794
650    12
$a anaplastický velkobuněčný lymfom $x farmakoterapie $x patologie $7 D017728
650    _2
$a heterografty $7 D064593
650    12
$a nádory plic $x farmakoterapie $7 D008175
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a organofosforové sloučeniny $x farmakologie $x terapeutické užití $7 D009943
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Matthews, Jamie D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
700    1_
$a Trigg, Ricky M $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK
700    1_
$a Montes-Mojarro, Ivonne A $u Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany
700    1_
$a Burke, G A Amos $u Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK $1 https://orcid.org/0000000326719972
700    1_
$a Fend, Falko $u Institute of Pathology and Neuropathology and Comprehensive Cancer Center Tübingen, University Hospital Tübingen, Eberhard-Karls-University, Tübingen, Germany
700    1_
$a Merkel, Olaf $u Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria
700    1_
$a Kenner, Lukas $u Department of Experimental Pathology and Laboratory Animal Pathology, Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Medical University of Vienna, Vienna, Austria $u Center for Biomarker Research in Medicine (CBmed) Vienna, Core-Lab2, Medical University of Vienna, Vienna, Austria
700    1_
$a Geoerger, Birgit $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France $u INSERM U1015, Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France
700    1_
$a Johnston, Robert $u Department of Paediatric Oncology/Haematology, Royal Belfast Hospital for Sick Children, Belfast, UK
700    1_
$a Murray, Matthew J $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK $u Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK $1 https://orcid.org/0000000244801147
700    1_
$a Riguad, Charlotte $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France
700    1_
$a Brugières, Laurence $u Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK $u Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000284394507
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 202, č. 5 (2023), s. 985-994
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37357529 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026105927 $b ABA008
999    __
$a ok $b bmc $g 2000104 $s 1202751
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 202 $c 5 $d 985-994 $e 20230625 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20231013
Back

Find record

Citation metrics

Archiving options